Journal of International Psychiatry

【Abstract】 Objective To explore the value of electronic biofeedback combined with escitalopram in patients with depression after large-scale cerebral infarction. Methods 84 patients with post-stroke depression admitted to our hospital from February 2022 to February 2023 were randomly divided into an observation group and a control group, with 42 cases in each group, using a random number table method. The control group was treated with escitalopram, while the observation group received electronic biofeedback therapy on the basis of the control group. Evaluate and compare the Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA), and General Quality of Life Inventory 74 (GQOLI-74) between two groups of patients. Results The results showed that the HAMD and HAMA scores after treatment in the two groups were lower than before treatment, with a statistically significant difference (P<0.05). The HAMD and HAMAI scores in the observation group were lower than those in the control group after treatment, with a statistically significant difference (P<0.05); The scores of GQOLI-74 in all dimensions after treatment in the two groups were higher than before treatment, and the difference was statistically significant (P<0.05). The scores of GQOLI-74 in all dimensions after treatment in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). Conclusion The combination of electronic biofeedback and escitalopram can effectively improve anxiety, depression, and quality of life in patients with depression after large-scale cerebral infarction.

【Key words】 Electronic biofeedback; Acecitalopram; Large area cerebral infarction; Depression; Quality of life